The public conversation about Ozempic is almost exclusively about weight. Which makes sense—semaglutide is an anti-obesity drug marketed around satiety, and its most visible effects are physical. The before and after pictures are weight photos. Clinical trials measured kilograms. The moral panic around it is about bodies.
But pharmacology keeps leaking out of its lane.
People taking GLP-1 receptor agonists have reported anecdotally and later in studies that their cravings for alcohol are reduced. Gambling impulses subside. Certain compulsive behaviors—reaching, urges without an object—seem to be silenced by the appetite for food. And now, in a study published this month in the journal Criminologyresearchers at Rutgers University found that current users of GLP-1 drugs a 62% weaker link between impulsivity and violent behaviorand a 52% weaker association between alcohol consumption and violence compared to former users – although the researchers note that this second figure showed more variance in the sensitivity test than the impulsivity finding.
Violence. This is not a scale.
How this drug really works
GLP-1 – glucagon-like peptide-1 – is a hormone that is naturally produced in the gut after eating. Its role in the digestive system is well known: it indicates satiety, slows down gastric emptying, and reduces insulin. Drugs that mimic this, including semaglutide (Ozempic, Wegovy), were developed primarily to exploit this function.
What was less expected is what happens when GLP-1 reaches the brain. GLP-1 receptors are widely distributed throughout the central nervous system—including the ventral tegmental area, nucleus accumbens, and prefrontal cortex. These are not digestive structures. They form the core of the dopaminergic reward system: the circuitry that drives motivation, desire, compulsion, and habit.
When GLP-1 agonists activate the receptors, something interesting happens. The reward value of various stimuli – food, alcohol, drugs, certain types of novelties – seems to decrease. Not through sedation or suppression of pleasure, but through a specific silencing of the ‘desiring’ signal. The impulse before the act. Before reaching the pull.
THE 2025 overview It’s titled “Suppress appetite and restore satiety”—language that, if you think about it for a moment, does a lot more than describe weight loss.
The angle of addiction
Addiction researchers have watched GLP-1 drugs with great interest. The overlap of reward circuits involved in compulsive eating and substance use disorders is not accidental, but structural. GLP-1 receptors in the nucleus accumbens modulates the release of dopamine it grounds the desire, regardless of what the desire is for.
Animal studies of alcohol, cocaine, and opioid self-administration have shown consistent reductions when GLP-1 agonists are used. Human data is catching up. Anecdotes have been accumulating long enough for researchers to conduct addiction studies of semaglutide—not as a weight-loss drug, but as a direct intervention for substance use disorders.
I find the logic here very interesting. Not because it’s a panacea—it clearly isn’t, and the mechanisms are still being unraveled—but because of what it entails. If the same receptor pathway mediates the desire for a meal, a drink, and a hit, then the “craving” was never just about the food. The word has always been a placeholder for something more fundamental: the volitional machinery of the brain. The system that generates the drive toward reward, regardless of what the reward is.
Identifying aggression and its complications
The data on violence are the strangest and most philosophically fruitful pieces of this. The Rutgers studypublished in June 2026, found that GLP-1 users showed significantly attenuated associations between impulsivity and violent behavior and alcohol consumption and violent behavior. The researchers are cautious—this is an observational, nonrandomized, controlled trial, and the sample of current users was small.
But if the finding is valid and replicated, it suggests that GLP-1 agonists somehow modulate the impulsive end of the aggression pathway. Which raises a question I keep coming back to: If appetite and aggression share enough of a neural architecture that a single class of drugs seems to dampen both, what does that say about the relationship between hunger and violence?
These are not obviously related drives. We have spent a long time treating them as separate psychological categories. Appetite belongs to nutrition science and eating disorders. Aggression belongs to criminology and psychiatry. They have different clinicians, different intervention frameworks, different moral registers. GLP-1 doesn’t seem to have gotten that memo.
What was the appetite really like
A more useful framework might be: appetite is not a single drive with multiple objects. This is the brain’s general desirability—the mechanism that generates directed motivation toward something that has been rewarding in the past or that the brain predicts will be rewarding. Food, sex, alcohol, substances, social status, certain types of conflict—these are all objects that the reward system can relate to.
A drug that silences this craving system would, in theory, reach all of them. Not equally, not uniformly, and not without side effects (evidence on GLP-1s and mood, including signs around depression, remains under active scrutiny – anyone currently using a GLP-1 drug should discuss mood changes with their prescriber). But structurally, a drug that affects the nucleus accumbens is not a diet that also happens to affect addiction. It is an intervention in the missing architecture of the human brain that happens to be packaged and approved as a diet pill.
That’s another thing. And I think it deserves a different kind of conversation – not a breathless one, but a more honest and to-the-point conversation than “Ozempic helps you eat less.”
Sovereign Mind lens
This is exactly the kind of problem that requires careful epistemic framing: when a cultural narrative about a drug, a behavior, or a human impulse solidifies into a frame that prevents us from asking the questions that the evidence already raises.
- Unlearning: The category of “appetite” as a distinct, food-specific drive is a legacy assumption no longer clearly supported by neuroscience. Similarly, the formulation of Ozempic as a weight-loss drug—and only that—is a commercial and regulatory artifact, not a biological fact. What would change the way we think about craving, compulsion, and even aggression if we started from the reward system instead of the behavior?
- Renovation: The cognitive conditions for examining this clearly require slowing down a media cycle that moves from a clinical finding to a lifestyle trend within days. Much of the reporting on GLP-1 and behavior is preliminary, controversial, and incomplete. The restorative impulse here is to resist the pressure to have a view—and to hold uncertainty as the most honest position available until the science matures.
- Protection: Both the moral panic surrounding Ozempic and the uncritical enthusiasm for him are manipulation vectors. Panic frames the drug as an attack on human authenticity, willpower, or embodied experience. Enthusiasm uses emerging behavioral data to position it as a civilizational solution. Both are ahead of the evidence. One form of intellectual self-defense is to recognize that neither narrative is science—and that the actual research is messier and more interesting than either.
An open question
I’m not saying that GLP-1 drugs are good or bad, or that we should expand their use to criminal justice applications, or that the Rutgers study means anything for violence prevention. The researchers themselves are aware of the limitations.
I’m interested in the question that these findings force: if the same neural pathways underlie food and drink cravings and the kind of impulsive reactivity that leads to aggression—what does that mean for understanding craving itself? What does it mean to treat them as separate moral and medical categories when they appear to be expressions of the same underlying system at the receptor level?
Ozempic does not answer this question. But Ozempic suddenly started asking this.
